Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16693057 | 1.00 | CYP2A6 (0.58) | CYP2A6RAB9AMAPTNPC1MAPK1 | |
| SCHEMBL4917815 | 0.81 | CYP2A6 (0.58) | CYP2A6RAB9AMAPTNPC1MAPK1 | |
| SCHEMBL16684694 | 0.77 | APP (0.48) | CYP2A6RAB9AMAPTHPGDSMN1; SMN2 | |
| SCHEMBL16684695 | 0.77 | APP (0.48) | CYP2A6RAB9AMAPTHPGDSMN1; SMN2 | |
| SCHEMBL16693152 | 0.77 | APP (0.48) | CYP2A6MAPTHPGDSMN1; SMN2GFER | |
| SCHEMBL16684587 | 0.77 | APP (0.48) | CYP2A6MAPTHPGDSMN1; SMN2GFER | |
| SCHEMBL21933161 | 0.75 | HPGD (0.54) | RAB9ANPC1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL21409023 | 0.75 | CYP2A6 (0.44) | CYP2A6MAPTHPGDSMN1; SMN2GFER | |
| SCHEMBL21409025 | 0.75 | CYP2A6 (0.44) | CYP2A6MAPTHPGDSMN1; SMN2GFER | |
| SCHEMBL15095310 | 0.74 | CYP2A6 (0.60) | CYP2A6RAB9AMAPTNPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115246795-B | Isoxazoline compound containing ether structure at 4-phenyl para-position, preparation method thereof and application thereof as insecticidal and bactericidal agent | 瑞普（天津）生物药业有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-115246795-A | Isoxazoline compound with 4-phenyl para-position containing ether structure, preparation thereof and application thereof as insecticide and bactericide | 瑞普（天津）生物药业有限公司 | 2022-10-28 | — | — | CN | disclosed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | CYP2A6 215/4885RAB9A 2549/4885MAPT 4180/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | CYP2A6 288/4885RAB9A 2112/4885MAPT 4449/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | CYP2A6 43/4885RAB9A 1700/4885MAPT 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.